Skip to Main content Skip to Navigation
New interface
Journal articles

Can we identify response markers to antihypertensive drugs? First results from the Ideal Trial.

Abstract : Current antihypertensive strategies do not take into account that individual characteristics may influence the magnitude of blood pressure (BP) reduction. Guidelines promote trial-and-error approaches with many different drugs. We conducted the Identification of the Determinants of the Efficacy of Arterial blood pressure Lowering drugs (IDEAL) Trial to identify factors associated with BP responses to perindopril and indapamide. IDEAL was a cross-over, double-blind, placebo-controlled trial, involving four 4-week periods: indapamide, perindopril and two placebo. Eligible patients were untreated, hypertensive and aged 25-70 years. The main outcome was systolic BP (SBP) response to drugs. The 112 participants with good compliance had a mean age of 52. One in every three participants was a woman. In middle-aged women, the SBP reduction from drugs was -11.5 mm Hg (indapamide) and -8.3 mm Hg (perindopril). In men, the response was significantly smaller: -4.8 mm Hg (indapamide) and -4.3 (perindopril) (P for sex differences 0.001 and 0.015, respectively). SBP response to perindopril decreased by 2 mm Hg every 10 years of age in both sexes (P=0.01). The response to indapamide increased by 3 mm Hg every 10 years of age gradient in women (P=0.02). Age and sex were important determinants of BP response for antihypertensive drugs in the IDEAL population. This should be taken into account when choosing drugs a priori.
Document type :
Journal articles
Complete list of metadata
Contributor : Yves Zerbib Connect in order to contact the contributor
Submitted on : Thursday, June 12, 2014 - 2:54:01 PM
Last modification on : Tuesday, September 13, 2022 - 2:46:07 PM


  • HAL Id : hal-01005386, version 1



Gueyffier F., Subtil F., Bejan-Angoulvant T., Yves Zerbib, Baguet Jp, et al.. Can we identify response markers to antihypertensive drugs? First results from the Ideal Trial.. Journal of Human Hypertension, 2014, pp.doi: 10.1038/jhh.2014.29. ⟨hal-01005386⟩



Record views